Frequency of demyelinating disease activity following immune checkpoint inhibitor cancer immunotherapy
J Neurol
.
2023 Oct;270(10):4707-4712.
doi: 10.1007/s00415-023-11933-6.
Epub 2023 Aug 19.
Authors
Shemonti Hasan
1
,
Onilia Zorio
1
,
B Mark Keegan
2
,
Brian G Weinshenker
2
3
,
Eoin P Flanagan
2
4
,
W Oliver Tobin
2
,
Orhun H Kantarci
2
,
Michel Toledano
2
,
Sean J Pittock
2
4
,
Sebastian Lopez-Chiriboga
5
,
Anastasia Zekeridou
2
4
,
Cristina Valencia-Sanchez
6
Affiliations
1
Department of Neurology, Mayo Clinic Arizona, 13400 East Shea Blvd, Scottsdale, AZ, 85259, USA.
2
Department of Neurology, Mayo Clinic, Rochester, MN, USA.
3
Department of Neurology, University of Virginia, Charlottesville, VA, USA.
4
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
5
Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.
6
Department of Neurology, Mayo Clinic Arizona, 13400 East Shea Blvd, Scottsdale, AZ, 85259, USA. valenciasanchez.cristina@mayo.edu.
PMID:
37597071
DOI:
10.1007/s00415-023-11933-6
No abstract available
Publication types
Letter
MeSH terms
Demyelinating Diseases* / chemically induced
Humans
Immune Checkpoint Inhibitors / adverse effects
Neoplasms* / drug therapy
Substances
Immune Checkpoint Inhibitors